Amaranth Medical

11 articles about Amaranth Medical

• Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT

  9/24/2018

  Amaranth Medical provided an update on the company’s sirolimus-eluting bioresorbable scaffold (BRS) products at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting during the following sessions

• Amaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDE

  10/26/2017

  New data to be presented at the meeting include nine-month imaging results from 12 of the 70 patients enrolled in the RENASCENT-III study of MAGNITUDE.

• Amaranth Medical Provides Clinical And Commercial Update On 115-micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

  5/16/2017

• Amaranth Medical 9-Months Clinical And Imaging Results Of The FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented At TCT

  11/2/2016

• Amaranth Medical Completes MEND-II And RENASCENT Studies And Initiates Study Of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

  10/15/2015

• Amaranth Medical Reports Findings From Two FORTITUDE Bioresorbable Scaffold Studies At EuroPCR 2015

  5/19/2015

• Amaranth Medical Announces Investment From Boston Scientific Corporation

  1/14/2014

• Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE&#0153 Bioresorbable Scaffold

  10/28/2013

• Amaranth Medical Raises $20 Million in Series B to Support Development of the FORTITUDE™ Bioresorbable Scaffold

  10/8/2013

• Insiders, New Investors to Join $25 Million Series B Round for Amaranth Medical

  6/17/2013

• Amaranth Medical Closes $7.5 Million Series A Financing To Advance The Development Of Bio-Absorbable Stents

  9/27/2006